The "late sodium current" (I<sub>NaL</sub>) is a sustained component of the fast Na<sup>+</sup> current of cardiac myocytes and neurons. As recently appreciated, common neurological and cardiac conditions are associated with abnormal I<sub>NaL</sub> enhancement, which may contribute to the pathogenesis of both electrical and contractile dysfunction. For this reason, I<sub>NaL</sub> has become an appealing pharmacological target, with a potentially broad range of therapeutic indications. The recent approval by the FDA of an I<sub>NaL</sub> blocker (ranolazine) for clinical use justifies the increased interest in I<sub>NaL</sub> as a pathogenic mechanism and the rapid evolution of the information concerning it. The review focuses on cardiac aspects of I<sub>NaL</sub> enhancement; it deals with the origin of I<sub>NaL</sub>, with its pathophysiological role and with the consequences of its pharmacological modulation. Both basic aspects and clinical evidence are discussed. © 2008 Elsevier Inc. All rights reserved.
Zaza, A., Belardinelli, L., & Shryock, J.C. (2008). Pathophysiology and pharmacology of the cardiac "late sodium current". PHARMACOLOGY & THERAPEUTICS, 119(3), 326-339.
Citazione: | Zaza, A., Belardinelli, L., & Shryock, J.C. (2008). Pathophysiology and pharmacology of the cardiac "late sodium current". PHARMACOLOGY & THERAPEUTICS, 119(3), 326-339. |
Tipo: | Articolo in rivista - Articolo scientifico |
Carattere della pubblicazione: | Scientifica |
Titolo: | Pathophysiology and pharmacology of the cardiac "late sodium current" |
Autori: | Zaza, A; Belardinelli, L; Shryock, JC |
Autori: | |
Data di pubblicazione: | 1-lug-2008 |
Lingua: | English |
Rivista: | PHARMACOLOGY & THERAPEUTICS |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.pharmthera.2008.06.001 |
Appare nelle tipologie: | 01 - Articolo su rivista |